X
(All Fields are required)
Report

PharmFree Scorecard
Conflict of Interest Policies at Academic Medical Centers


Quick Summary

Most of the 150 U.S. medical schools are failing when it comes to building strong conflict of interest policies to limit pharmaceutical marketing on campus, according to the American Medical Student Association (AMSA) PharmFree Scorecard released today.

PharmFree Scorecard

Contact

Linda Paris, Tel: 202-540-6354

Report Project

Report Topic

Most of the 150 U.S. medical schools are failing when it comes to building strong conflict of interest policies to limit pharmaceutical marketing on campus, according to the American Medical Student Association (AMSA) PharmFree Scorecard released today. Only seven institutions received 'A's for their conflict of interest policies.

“The schools that earned ‘A’ and ‘B’ scores are to be commended for setting a high bar and aggressively moving forward to ensure medical education, training and patient care is free of commercial bias,” says RxP executive director Robert Restuccia. “While we still have a long way to go, we are optimistic that the growing momentum for reform will change the landscape and there will be great improvement next year.”

To check out the Scorecard, go to www.amsascorecard.org.

Date added:
Jul 3, 2008
Contact:
Linda Paris, Tel: 202-540-6354
Project:
Pew Prescription Project
Topic:
Conflicts of Interest

Related Resources

''Already Feeling the Heat''

Media Coverage

"The legislation requiring public disclosure of the financial relationships between healthcare vendors and physicians has been widely discussed in policy circles for years. Critics claimed payments for speaking, consulting, research or even the small trinkets and meals delivered during routine sales calls unduly influenced physician choices and inflated healthcare costs. To combat those effects, Congress required public reporting of those payments in a publicly accessible database. The legislation, labeled the Physician Payment Sunshine Act, was included in the 2010 healthcare reform law."

More

Letter from Pew to CMS Regarding Physician Payments Sunshine Act

Issue Brief

Prescription project director Danny Carlat identifies issues with the Physician Payments Sunshine Act requiring further clarification and guidance. Addressing those would ensure that manufacturers can appropriately implement the final rule, and enable consumers to benefit from transparency reports published by the Centers for Medicare & Medicaid Services.

More

Advancing Integrity in Medical Education

Other Resource
The Pew Charitable Trusts is working to decrease the influence of pharmaceutical marketing on doctors’ practices. With a three-year grant from the Attorney General Consumer and Prescriber Education Grant Program, Pew is collaborating several partners to improve conflict-of-interest policies within the 158 medical schools and 400 major teaching hospitals in the United States. More

Pew Comments on Centers for Medicaid and Medicare Services' Information Collection Activities Draft Guidance

Issue Brief

The Pew Charitable Trusts appreciates this opportunity to submit comments to CMS's "Information Collection Activities" draft guidance. We suggest that both the research and non-research payment templates be modified in order to make it easier for consumers to identify which drugs, devices, biologicals, or medical supplies are associated with particular transfers of value.

More

One Step Closer to Medical Transparency: Pew's Analysis of the Final Rule for the Physician Payments Sunshine Act

Other Resource
On Feb. 1, 2013, the Centers for Medicare & Medicaid Services published the final rule guiding implementation of the Physician Payments Sunshine Act, which Congress passed as part of the Affordable Care Act in March 2010 to increase transparency in the relationships between physicians and drug and medical device makers. Here are some of the highlights. More